Lido Advisors LLC Makes New Investment in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Posted by on Mar 12th, 2023

Lido Advisors LLC acquired a new position in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX – Get Rating) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 50,031 shares of the company’s stock, valued at approximately $233,000.

Several other hedge funds also recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP boosted its holdings in shares of GoodRx by 12.5% in the 3rd quarter. Dimensional Fund Advisors LP now owns 19,383 shares of the company’s stock valued at $91,000 after buying an additional 2,153 shares during the period. Carmel Capital Partners LLC boosted its holdings in shares of GoodRx by 6.8% in the 3rd quarter. Carmel Capital Partners LLC now owns 37,248 shares of the company’s stock valued at $174,000 after buying an additional 2,372 shares during the period. Raymond James & Associates boosted its holdings in shares of GoodRx by 24.0% in the 1st quarter. Raymond James & Associates now owns 13,806 shares of the company’s stock valued at $267,000 after buying an additional 2,675 shares during the period. Boothe Investment Group Inc. boosted its holdings in shares of GoodRx by 1.9% in the 3rd quarter. Boothe Investment Group Inc. now owns 212,324 shares of the company’s stock valued at $992,000 after buying an additional 3,935 shares during the period. Finally, Advisor Group Holdings Inc. boosted its holdings in shares of GoodRx by 17.6% in the 1st quarter. Advisor Group Holdings Inc. now owns 28,454 shares of the company’s stock valued at $414,000 after buying an additional 4,265 shares during the period. 35.22% of the stock is owned by institutional investors and hedge funds.

GoodRx Stock Up 4.9 %

GDRX stock opened at $5.76 on Friday. The company has a current ratio of 12.05, a quick ratio of 12.05 and a debt-to-equity ratio of 0.80. The firm’s 50-day moving average is $5.32 and its two-hundred day moving average is $5.24. GoodRx Holdings, Inc. has a 52 week low of $3.82 and a 52 week high of $20.59. The company has a market capitalization of $2.29 billion, a price-to-earnings ratio of -82.27, a price-to-earnings-growth ratio of 10.69 and a beta of 0.84.

Analyst Ratings Changes

Several research analysts have recently commented on GDRX shares. Cowen decreased their price target on shares of GoodRx to $6.50 in a report on Wednesday, November 16th. Wells Fargo & Company lifted their price target on shares of GoodRx from $5.50 to $6.00 and gave the company an “equal weight” rating in a report on Wednesday, March 1st. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of GoodRx from $7.00 to $8.00 and gave the company a “hold” rating in a research report on Tuesday, March 7th. Citigroup lifted their price objective on shares of GoodRx from $7.00 to $7.50 and gave the company a “buy” rating in a research report on Wednesday. Finally, DA Davidson cut their price objective on shares of GoodRx to $5.00 in a research report on Tuesday, November 15th. Fourteen investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, GoodRx presently has an average rating of “Hold” and an average target price of $8.00.

GoodRx Company Profile

(Get Rating)

GoodRx Holdings, Inc, through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States.

Featured Articles

Want to see what other hedge funds are holding GDRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GoodRx Holdings, Inc. (NASDAQ:GDRX – Get Rating).

Institutional Ownership by Quarter for GoodRx (NASDAQ:GDRX)

Receive News & Ratings for GoodRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GoodRx and related companies with MarketBeat.com's FREE daily email newsletter.